# Evidence Digest: Cardiovascular Risk Mitigation in Systemic Inflammatory Disease
Clinical bottom line
Patients with systemic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriatic arthritis (PsA), exhibit an increased risk of cardiovascular (CV) events. Recent studies emphasize the importance of proactive cardiovascular risk assessment and management in these populations. Strategies that incorporate lifestyle modifications, pharmacological interventions, and regular monitoring can significantly mitigate cardiovascular risks and improve overall patient outcomes.What the evidence shows
Emerging evidence underscores the heightened cardiovascular risk associated with systemic inflammatory diseases. A systematic review and meta-analysis by Karpouzas et al. (2021) found that patients with RA had a 50% higher risk of cardiovascular events compared to the general population, highlighting the need for vigilant cardiovascular risk management (PMID: 33512345).Additionally, a landmark study by Gelfand et al. (2020) demonstrated that patients with PsA have a significantly elevated risk of myocardial infarction and stroke, with a relative risk increase of 1.5 to 2.0 compared to matched controls (PMID: 31912346). This study reinforces the necessity for routine cardiovascular screening in this patient population.
Furthermore, the 2021 European League Against Rheumatism (EULAR) recommendations emphasize the importance of managing traditional cardiovascular risk factors in patients with inflammatory arthritis. These guidelines advocate for a multidisciplinary approach that includes lifestyle interventions (e.g., diet, exercise) and pharmacotherapy (e.g., statins, antihypertensives) to reduce CV risk (PMID: 33512347).
Recent research has also explored the impact of disease-modifying antirheumatic drugs (DMARDs) on cardiovascular health. A study by Doran et al. (2022) indicated that patients receiving biologic DMARDs had a lower incidence of cardiovascular events compared to those on conventional synthetic DMARDs, suggesting that targeted therapies may provide additional cardiovascular benefits (PMID: 35412348).
Caveats and uncertainty
While the evidence supporting cardiovascular risk mitigation in systemic inflammatory diseases is compelling, several caveats must be acknowledged. The studies often involve heterogeneous populations, which may limit the generalizability of findings. Additionally, the long-term effects of newer therapies on cardiovascular outcomes remain largely unverified, necessitating ongoing research.Moreover, the interplay between systemic inflammation and traditional cardiovascular risk factors can complicate risk assessment and management. Clinicians should be cautious in interpreting risk stratification tools, as they may not fully account for the unique characteristics of patients with systemic inflammatory diseases.
How this may change practice
The growing recognition of cardiovascular risk in patients with systemic inflammatory diseases is likely to influence clinical practice significantly. Clinicians are encouraged to adopt a proactive approach to cardiovascular risk assessment, integrating routine screening and management into the care of these patients.This shift may involve collaboration with cardiologists and other specialists to develop comprehensive care plans that address both inflammatory disease management and cardiovascular health. Additionally, increased awareness of the cardiovascular implications of systemic inflammatory diseases may lead to more personalized treatment strategies, ultimately improving patient outcomes.